Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Book of Meme (BOME) To Soar Higher? This Emerging Fractal Saying Yes!

Book of Meme (BOME) To Soar Higher? This Emerging Fractal Saying Yes!

2025/07/07 11:40
By:

Date: Mon, July 07, 2025 | 05:38 AM GMT

As Q3 begins, the cryptocurrency market is extending its momentum from Q2, with Ethereum (ETH) trading near $2,575 after gaining over 63% in the past 90 days. In the memecoin space, Solana-based tokens continue to attract attention — and Book of Meme (BOME) is now flashing a chart pattern that could hint at a powerful upside move.

BOME has already climbed over 55% in the past 90 days. But beyond the recent gains, what’s catching more attention is the emerging fractal pattern that BOME is forming — one that closely mirrors BONK’s recent breakout structure.

Book of Meme (BOME) To Soar Higher? This Emerging Fractal Saying Yes! image 0 Source: Coinmarketcap

BOME Mirrors BONK’s Breakout Structure

On the daily chart, BONK recently completed a textbook falling wedge pattern — a classic bullish reversal setup. The breakout was confirmed when BONK decisively moved above the wedge structure and flipped its 50-day, 100-day, and 200-day moving averages. That move kicked off a strong 77% rally, with the price rising from around $0.00001312 to nearly $0.00002319.

BONK and BOME Fractal Chart/Coinsprobe (Source: Tradingview)

Now, BOME appears to be following a nearly identical setup.

BOME has also broken out of a falling wedge pattern and is currently consolidating just beneath its 50-day and 100-day moving averages, near the $0.001791 resistance zone. This zone is key — it’s the same kind of consolidation that BONK saw before its explosive breakout.

The similarities between both structures are striking. If this fractal continues to play out, BOME may be poised for a major move higher.

What’s Next for BOME?

For BOME to confirm this bullish fractal, it must decisively close above the 50-day moving average (currently near $0.001791) with strong volume. A breakout above this level would likely clear the path toward its 200-day MA at $0.002517 — a potential 57% upside from current prices.

However, confirmation is crucial.

Until BOME breaks and holds above its immediate resistance zone, the setup remains unconfirmed, and the risk of sideways consolidation remains. Still, the fractal resemblance to BONK gives bulls a reason to watch closely.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market